Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 8 2 2014 06 15 21 26 Ahmad Ahmadzadeh Health research institute, Research Center of Thalassemia & Hemoglobinopathy,Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Mir Saeed Yekaninejad Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Mohamad H Jalili Department of internal medicine, school of medicine, Tehran University of medical sciences, Tehran, Iran. Mohammad Bahadoram Department of internal medicine, school of medicine, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran. Mehdi Efazat Department of internal medicine, school of medicine, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran. Mohammad Seghatoleslami Health research institute, Research Center of Thalassemia & Hemoglobinopathy,Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Fatemeh Yazdi Department of internal medicine, Ganjavian hospital, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran. Mozhdeh Mahdipour Department of surgery, Arvand hospital, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran. Armita Valizadeh Department of Anatomy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Najmaldin Saki Health research institute, Research Center of Thalassemia & Hemoglobinopathy,Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 2015 10 14 In this study we surveyed the average survival time of the treated Hodgkin's lymphoma patients and also the side effects and malignancies occurring secondary to the treatment. This is a retrospective study of patients referring to Ahwaz's Shafa hospital in a period of 10 years diagnosed with Hodgkin's lymphoma without any age restriction. After gathering all their data, we calculated their survival rate and the chance for a relapse and the secondary malignancies. 389 patients were included in the study with an average age of 27.5 years old and they had received only chemotherapy regimens. 87.9% of them had been treated by ABVD and 12.1 % by Stanford V regimen. 23.1% of them experienced a relapse and 13.1% of all patients, passed away during the study. Secondary malignancies were observed in 11 cases. An overall mean survival time of 295.31 months was resulted. The secondary malignancies after treating Hodgkin's lymphoma patients are different between chemotherapy regimens and chemotherapy - radiotherapy. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/424 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/424/373